MicroRNAs associated with HBV infection And HBV-related HCC

Theranostics

Volumn 4, Issue 12, 2014, Pages 1176-1192

  Xie, Kun Lin ^a   Zhang, Yan Ge ^a   Liu, Jun ^a   Zeng, Yong ^a   Wu, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Diagnosis; Hepatitis B virus; Hepatocellular carcinoma; MicroRNA; Therapy

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 122; MICRORNA 125A; MICRORNA 125P; MICRORNA 141; MICRORNA 146A; MICRORNA 152; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 17; MICRORNA 18A; MICRORNA 193P; MICRORNA 199A; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 22; MICRORNA 23B; MICRORNA 26A; MICRORNA 29A; MICRORNA 29C; MICRORNA 34A; MICRORNA 372; MICRORNA 501; MICRORNA 548; MICRORNA 92; MICRORNA 99A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS RELATED HEPATOCELLULAR CARCINOMA; HUMAN; IMMUNE SYSTEM; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METASTASIS; NONHUMAN; ONCOGENE; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; ANIMAL; GENETICS; LIVER TUMOR; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MICRORNAS;

EID: 84907984864     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8715     Document Type: Article

References (153)

1. Huang S, He X. The role of micrornas in liver cancer progression. Br J Cancer. 2011; 104: 235-240.
2. Lee Y, Ahn C, Han J, et al. The nuclear rnase iii drosha initiates microrna processing. Nature. 2003; 425: 415-419.
3. Lund E, Guttinger S, Calado A, et al. Nuclear export of microrna precursors. Science. 2004; 303: 95-98.
4. Kiss T. Small nucleolar rnas: An abundant group of noncoding rnas with diverse cellular functions. Cell. 2002; 109: 145-148.
5. Kim VN. Microrna biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6: 376-385.
6. Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of rna interference. Nature. 2001; 409: 363-366.
7. Yekta S, Shih IH, Bartel DP. Microrna-directed cleavage of hoxb8 mrna. Science. 2004; 304: 594-596.
8. Zeng Y. Principles of micro-rna production and maturation. Oncogene. 2006; 25: 6156-6162.
9. Kim VN, Han J, Siomi MC. Biogenesis of small rnas in animals. Nat Rev Mol Cell Biol. 2009; 10: 126-139.
10. Braconi C, Huang N, Patel T. Microrna-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010; 51: 881-890.
11. Wei X, Xiang T, Ren G, et al. Mir-101 is down-regulated by the hepatitis b virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3a. Cell Signal. 2013; 25: 439-446.
12. Wei X, Tan C, Tang C, et al. Epigenetic repression of mir-132 expression by the hepatitis b virus x protein in hepatitis b virus-related hepatocellular carcinoma. Cell Signal. 2013; 25: 1037-1043.
13. Liu WH, Yeh SH, Chen PJ. Role of micrornas in hepatitis b virus replication and pathogenesis. Biochim Biophys Acta. 2011; 1809: 678-685.
14. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis b virus infection: New estimates of age-specific hbsag seroprevalence and endemicity. Vaccine. 2012; 30: 2212-2219.
15. Wang Y, Jiang L, Ji X, et al. Hepatitis b viral rna directly mediates down-regulation of the tumor suppressor microrna mir-15a/mir-16-1 in hepatocytes. J Biol Chem. 2013; 288: 18484-18493.
16. Su C, Hou Z, Zhang C, et al. Ectopic expression of microrna-155 enhances innate antiviral immunity against hbv infection in human hepatoma cells. Virol J. 2011; 8: 354.
17. Li Y, Xie J, Xu X, et al. Microrna-548 down-regulates host antiviral response via direct targeting of ifn-lambda1. Protein Cell. 2013; 4: 130-141.
18. Xie Q, Chen X, Lu F, et al. Aberrant expression of microrna 155 may accelerate cell proliferation by targeting sex-determining region y box 6 in hepatocellular carcinoma. Cancer. 2012; 118: 2431-2442.
19. Mahajan VS, Drake A, Chen J. Virus-specific host mirnas: Antiviral defenses or promoters of persistent infection? Trends Immunol. 2009; 30: 1-7.
20. Wang S, Zhang X, Ju Y, et al. Microrna-146a feedback suppresses t cell immune function by targeting stat1 in patients with chronic hepatitis b. J Immunol. 2013; 191: 293-301.
21. Yang P, Li QJ, Feng Y, et al. Tgf-beta-mir-34a-ccl22 signaling-induced treg cell recruitment promotes venous metastases of hbv-positive hepatocellular carcinoma. Cancer Cell. 2012; 22: 291-303.
22. Lecellier CH, Dunoyer P, Arar K, et al. A cellular microrna mediates antiviral defense in human cells. Science. 2005; 308: 557-560.
23. Zhang GL, Li YX, Zheng SQ, et al. Suppression of hepatitis b virus replication by microrna-199a-3p and microrna-210. Antiviral Res. 2010; 88: 169-175.
24. Chen Y, Shen A, Rider PJ, et al. A liver-specific microrna binds to a highly conserved rna sequence of hepatitis b virus and negatively regulates viral gene expression and replication. FASEB J. 2011; 25: 4511-4521.
25. Liu N, Zhang J, Jiao T, et al. Hepatitis b virus inhibits apoptosis of hepatoma cells by sponging mir-15a/16 cluster. J Virol. 2013.
26. Jung YJ, Kim JW, Park SJ, et al. C-myc-mediated overexpression of mir-17-92 suppresses replication of hepatitis b virus in human hepatoma cells. J Med Virol. 2013; 85: 969-978.
27. Potenza N, Papa U, Mosca N, et al. Human microrna hsa-mir-125a-5p interferes with expression of hepatitis b virus surface antigen. Nucleic Acids Res. 2011; 39: 5157-5163.
28. Wang Y, Lu Y, Toh ST, et al. Lethal-7 is down-regulated by the hepatitis b virus x protein and targets signal transducer and activator of transcription 3. J Hepatol. 2010; 53: 57-66.
29. Zhang T, Zhang J, Cui M, et al. Hepatitis b virus x protein inhibits tumor suppressor mir-205 through inducing hypermethylation of mir-205 promoter to enhance carcinogenesis. Neoplasia. 2013; 15: 1282-1291.
30. Lopez-Cabrera M, Letovsky J, Hu KQ, et al. Transcriptional factor c/ebp binds to and transactivates the enhancer element ii of the hepatitis b virus. Virology. 1991; 183: 825-829.
31. Lopez-Cabrera M, Letovsky J, Hu KQ, et al. Multiple liver-specific factors bind to the hepatitis b virus core/pregenomic promoter: Trans-activation and repression by ccaat/enhancer binding protein. Proc Natl Acad Sci U S A. 1990; 87: 5069-5073.
32. Wang B, Majumder S, Nuovo G, et al. Role of microrna-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in c57bl/6 mice. Hepatology. 2009; 50: 1152-1161.
33. Wang J, Liu X, Wu H, et al. Creb up-regulates long non-coding rna, hulc expression through interaction with microrna-372 in liver cancer. Nucleic Acids Res. 2010; 38: 5366-5383.
34. Kim BK, Lim SO, Park YG. Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis b virus replication. Hepatology. 2008; 48: 361-373.
35. Raney AK, Johnson JL, Palmer CN, et al. Members of the nuclear receptor superfamily regulate transcription from the hepatitis b virus nucleocapsid promoter. J Virol. 1997; 71: 1058-1071.
36. Hu W, Wang X, Ding X, et al. Microrna-141 represses hbv replication by targeting ppara. PloS one. 2012; 7: e34165.
37. Ori A, Zauberman A, Doitsh G, et al. P53 binds and represses the hbv enhancer: An adjacent enhancer element can reverse the transcription effect of p53. EMBO J. 1998; 17: 544-553.
38. Wang S, Qiu L, Yan X, et al. Loss of microrna 122 expression in patients with hepatitis b enhances hepatitis b virus replication through cyclin g(1) -modulated p53 activity. Hepatology. 2012; 55: 730-741.
39. Qiu L, Fan H, Jin W, et al. Mir-122-induced down-regulation of ho-1 negatively affects mir-122-mediated suppression of hbv. Biochem Biophys Res Commun. 2010; 398: 771-777.
40. Jin J, Tang S, Xia L, et al. Microrna-501 promotes hbv replication by targeting hbxip. Biochem Biophys Res Commun. 2013; 430: 1228-1233.
41. Guo H, Liu H, Mitchelson K, et al. Micrornas-372/373 promote the expression of hepatitis b virus through the targeting of nuclear factor i/b. Hepatology. 2011; 54: 808-819.
42. Zhang X, Zhang E, Ma Z, et al. Modulation of hepatitis b virus replication and hepatocyte differentiation by microrna-1. Hepatology. 2011; 53: 1476-1485.
43. Datta J, Kutay H, Nasser MW, et al. Methylation mediated silencing of microrna-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008; 68: 5049-5058.
44. Reese V, Ondracek C, Rushing C, et al. Multiple nuclear receptors may regulate hepatitis b virus biosynthesis during development. Int J Biochem Cell Biol. 2011; 43: 230-237.
45. Zhang X, Liu S, Hu T, et al. Up-regulated microrna-143 transcribed by nuclear factor kappa b enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology. 2009; 50: 490-499.
46. Huang J, Wang Y, Guo Y, et al. Down-regulated microrna-152 induces aberrant DNA methylation in hepatitis b virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010; 52: 60-70.
47. Kim JW, Lee SH, Park YS, et al. Replicative activity of hepatitis b virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis b virus infection. Intervirology. 2011; 54: 316-325.
48. Wu G, Yu F, Xiao Z, et al. Hepatitis b virus x protein downregulates expression of the mir-16 family in malignant hepatocytes in vitro. Br J Cancer. 2011; 105: 146-153.
49. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the mir-17-92 polycistron and mir-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol. 2008; 173: 856-864.
50. Gao P, Wong CC, Tung EK, et al. Deregulation of microrna expression occurs early and accumulates in early stages of hbv-associated multistep hepatocarcinogenesis. J Hepatol. 2011; 54: 1177-1184.
51. Li H, Li Y, Liu D, et al. Mir-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. Cell Physiol Biochem. 2013; 32: 448-458.
52. Lan SH, Wu SY, Zuchini R, et al. Autophagy suppresses tumorigenesis of hepatitis b virus-associated hepatocellular carcinoma through degradation of mir-224. Hepatology. 2013.
53. Wang C, Song B, Song W, et al. Underexpressed microrna-199b-5p targets hypoxia-inducible factor-1alpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2011; 26: 1630-1637.
54. Zhang WY, Cai N, Ye LH, et al. Transformation of human liver l-o2 cells mediated by stable hbx transfection. Acta Pharmacol Sin. 2009; 30: 1153-1161.
55. Scisciani C, Vossio S, Guerrieri F, et al. Transcriptional regulation of mir-224 upregulated in human hccs by nfkappab inflammatory pathways. J Hepatol. 2012; 56: 855-861.
56. Han H, Sun D, Li W, et al. A c-myc-microrna functional feedback loop affects hepatocarcinogenesis. Hepatology. 2013; 57: 2378-2389.
57. Shen J, Wang S, Zhang YJ, et al. Genome-wide aberrant DNA methylation of microrna host genes in hepatocellular carcinoma. Epigenetics. 2012; 7: 1230-1237.
58. Song K, Han C, Zhang J, et al. Epigenetic regulation of microrna-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus x protein in hepatocellular carcinoma cells. Hepatology. 2013.
59. Belloni L, Pollicino T, De Nicola F, et al. Nuclear hbx binds the hbv minichromosome and modifies the epigenetic regulation of cccdna function. Proc Natl Acad Sci U S A. 2009; 106: 19975-19979.
60. Wang Y, Toh HC, Chow P, et al. Microrna-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 2012; 26: 3032-3041.
61. Shi XY, Zhang YY, Zhou XW, et al. Hepatitis b virus x protein regulates the mezh2 promoter via the e2f1-binding site in aml12 cells. Chin J Cancer. 2011; 30: 273-279.
62. Au SL, Wong CC, Lee JM, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor micrornas to promote liver cancer metastasis. Hepatology. 2012; 56: 622-631.
63. Ren M, Qin D, Li K, et al. Correlation between hepatitis b virus protein and microrna processor drosha in cells expressing hbv. Antiviral Res. 2012; 94: 225-231.
64. Liu AM, Zhang C, Burchard J, et al. Global regulation on microrna in hepatitis b virus-associated hepatocellular carcinoma. OMICS. 2011; 15: 187-191.
65. Wu J, Zhang XJ, Shi KQ, et al. Hepatitis b surface antigen inhibits mica and micb expression via induction of cellular mirnas in hepatocellular carcinoma cells. Carcinogenesis. 2014; 35: 155-163.
66. Li C, Wang Y, Wang S, et al. Hepatitis b virus mrna-mediated mir-122 inhibition upregulates pttg1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol. 2013; 87: 2193-2205.
67. Longerich T, Mueller MM, Breuhahn K, et al. Oncogenetic tree modeling of human hepatocarcinogenesis. Int J Cancer. 2012; 130: 575-583.
68. Liu C, Yu J, Yu S, et al. Microrna-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol. 2010; 53: 98-107.
69. Qiu X, Dong S, Qiao F, et al. Hbx-mediated mir-21 upregulation represses tumor-suppressor function of pdcd4 in hepatocellular carcinoma. Oncogene. 2013; 32: 3296-3305.
70. Nakatani T, Roy G, Fujimoto N, et al. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn J Cancer Res. 2001; 92: 249-256.
71. Yu MW, Chang HC, Chang SC, et al. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis b- and c-related risk. Hepatology. 2003; 38: 1393-1400.
72. Jiang R, Deng L, Zhao L, et al. Mir-22 promotes hbv-related hepatocellular carcinoma development in males. Clin Cancer Res. 2011; 17: 5593-5603.
73. Liu WH, Yeh SH, Lu CC, et al. Microrna-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology. 2009; 136: 683-693.
74. Chen PJ, Yeh SH, Liu WH, et al. Androgen pathway stimulates microrna-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology. 2012; 56: 632-643.
75. Sampson VB, Rong NH, Han J, et al. Microrna let-7a down-regulates myc and reverts myc-induced growth in burkitt lymphoma cells. Cancer Res. 2007; 67: 9762-9770.
76. Johnson SM, Grosshans H, Shingara J, et al. Ras is regulated by the let-7 microrna family. Cell. 2005; 120: 635-647.
77. Lee YS, Dutta A. The tumor suppressor microrna let-7 represses the hmga2 oncogene. Genes Dev. 2007; 21: 1025-1030.
78. Wu CS, Yen CJ, Chou RH, et al. Downregulation of microrna-15b by hepatitis b virus x enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced globo h expression. Int J Cancer. 2013.
79. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin g1 is a target of mir-122a, a microrna frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007; 67: 6092-6099.
80. Xu T, Zhu Y, Xiong Y, et al. Microrna-195 suppresses tumorigenicity and regulates g1/s transition of human hepatocellular carcinoma cells. Hepatology. 2009; 50: 113-121.
81. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microrna delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137: 1005-1017.
82. Park IY, Sohn BH, Yu E, et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis b virus x protein. Gastroenterology. 2007; 132: 1476-1494.
83. Tong A, Gou L, Lau QC, et al. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis b virus x protein. J Proteome Res. 2009; 8: 1037-1046.
84. Xu L, Beckebaum S, Iacob S, et al. Microrna-101 inhibits human hepatocellular carcinoma progression through ezh2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 2013.
85. Noh JH, Chang YG, Kim MG, et al. Mir-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 2013; 335: 455-462.
86. Zhang J, Yang Y, Yang T, et al. Microrna-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 2010; 103: 1215-1220.
87. Zhang S, Shan C, Kong G, et al. Microrna-520e suppresses growth of hepatoma cells by targeting the nf-kappab-inducing kinase (nik). Oncogene. 2012; 31: 3607-3620.
88. Zhang JF, He ML, Fu WM, et al. Primate-specific microrna-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology. 2011; 54: 2137-2148.
89. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related micrornas in hepatocellular carcinoma. Hepatology. 2008; 47: 897-907.
90. Zeng L, Yu J, Huang T, et al. Differential combinatorial regulatory network analysis related to venous metastasis of hepatocellular carcinoma. BMC Genomics. 2012; 13 Suppl 8: S14.
91. Firrincieli D, Boissan M, Chignard N. Epithelial-mesenchymal transition in the liver. Gastroenterol Clin Biol. 2010; 34: 523-528.
92. Reichl P, Haider C, Grubinger M, et al. Tgf-beta in epithelial to mesenchymal transition and metastasis of liver carcinoma. Curr Pharm Des. 2012; 18: 4135-4147.
93. Coulouarn C, Factor VM, Andersen JB, et al. Loss of mir-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009; 28: 3526-3536.
94. Yang H, Fang F, Chang R, et al. Microrna-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013; 58: 205-217.
95. Kim T, Veronese A, Pichiorri F, et al. P53 regulates epithelial-mesenchymal transition through micrornas targeting zeb1 and zeb2. J Exp Med. 2011; 208: 875-883.
96. Li N, Fu H, Tie Y, et al. Mir-34a inhibits migration and invasion by down-regulation of c-met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009; 275: 44-53.
97. Salvi A, Sabelli C, Moncini S, et al. Microrna-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J. 2009; 276: 2966-2982.
98. Zhang JP, Zeng C, Xu L, et al. Microrna-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting met/snail signaling. Oncogene. 2013.
99. Kong G, Zhang J, Zhang S, et al. Upregulated microrna-29a by hepatitis b virus x protein enhances hepatoma cell migration by targeting pten in cell culture model. PloS one. 2011; 6: e19518.
100. Garofalo M, Di Leva G, Romano G, et al. Mir-221&222 regulate trail resistance and enhance tumorigenicity through pten and timp3 downregulation. Cancer Cell. 2009; 16: 498-509.
101. Wong QW, Ching AK, Chan AW, et al. Mir-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing akt signaling. Clin Cancer Res. 2010; 16: 867-875.
102. Xu X, Fan Z, Kang L, et al. Hepatitis b virus x protein represses mirna-148a to enhance tumorigenesis. J Clin Invest. 2013; 123: 630-645.
103. Hou J, Lin L, Zhou W, et al. Identification of mirnomes in human liver and hepatocellular carcinoma reveals mir-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011; 19: 232-243.
104. Yan H, Dong X, Zhong X, et al. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in mir-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog. 2013.
105. Arzumanyan A, Friedman T, Kotei E, et al. Epigenetic repression of e-cadherin expression by hepatitis b virus x antigen in liver cancer. Oncogene. 2012; 31: 563-572.
106. Sun Z, Han Q, Zhou N, et al. Microrna-9 enhances migration and invasion through klf17 in hepatocellular carcinoma. Mol Oncol. 2013; 7: 884-894.
107. Meng Z, Fu X, Chen X, et al. Mir-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology. 2010; 52: 2148-2157.
108. Ji J, Zhao L, Budhu A, et al. Let-7g targets collagen type i alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol. 2010; 52: 690-697.
109. Tsai WC, Hsu PW, Lai TC, et al. Microrna-122, a tumor suppressor microrna that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009; 49: 1571-1582.
110. Bai S, Nasser MW, Wang B, et al. Microrna-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009; 284: 32015-32027.
111. Stross L, Gunther J, Gasteiger G, et al. Foxp3+ regulatory t cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis b virus infection in mice. Hepatology. 2012; 56: 873-883.
112. Fabbri M, Paone A, Calore F, et al. Micrornas bind to toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012; 109: E2110-2116.
113. Waidmann O, Bihrer V, Pleli T, et al. Serum microrna-122 levels in different groups of patients with chronic hepatitis b virus infection. J Viral Hepat. 2012; 19: e58-65.
114. Arataki K, Hayes CN, Akamatsu S, et al. Circulating microrna-22 correlates with microrna-122 and represents viral replication and liver injury in patients with chronic hepatitis b. J Med Virol. 2013; 85: 789-798.
115. Raimondo G, Pollicino T, Romano L, et al. A 2010 update on occult hepatitis b infection. Pathol Biol (Paris). 2010; 58: 254-257.
116. Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis b virus infection. J Hepatol. 2007; 46: 160-170.
117. Chen Y, Li L, Zhou Z, et al. A pilot study of serum microrna signatures as a novel biomarker for occult hepatitis b virus infection. Med Microbiol Immunol. 2012; 201: 389-395.
118. Chen CJ, Lee MH. Early diagnosis of hepatocellular carcinoma by multiple micrornas: Validity, efficacy, and cost-effectiveness. J Clin Oncol. 2011; 29: 4745-4747.
119. Li LM, Hu ZB, Zhou ZX, et al. Serum microrna profiles serve as novel biomarkers for hbv infection and diagnosis of hbv-positive hepatocarcinoma. Cancer Res. 2010; 70: 9798-9807.
120. Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microrna-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012; 56: 167-175.
121. Zhou J, Yu L, Gao X, et al. Plasma microrna panel to diagnose hepatitis b virus-related hepatocellular carcinoma. J Clin Oncol. 2011; 29: 4781-4788.
122. Muthiah M, Park IK, Cho CS. Nanoparticle-mediated delivery of therapeutic genes: Focus on mirna therapeutics. Expert Opin Drug Deliv. 2013; 10: 1259-1273.
123. Hsu SH, Yu B, Wang X, et al. Cationic lipid nanoparticles for therapeutic delivery of sirna and mirna to murine liver tumor. Nanomedicine. 2013; 9: 1169-1180.
124. Wang X, Yu B, Ren W, et al. Enhanced hepatic delivery of sirna and microrna using oleic acid based lipid nanoparticle formulations. J Control Release. 2013; 172: 690-698.
125. Liang GF, Zhu YL, Sun B, et al. Plga-based gene delivering nanoparticle enhance suppression effect of mirna in hepg2 cells. Nanoscale Res Lett. 2011; 6: 447.
126. Li D, Liu X, Lin L, et al. Microrna-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 2011; 286: 36677-36685.
127. Bader AG. Mir-34-a microrna replacement therapy is headed to the clinic. Front Genet. 2012; 3: 120.
128. Zhang M, Zhou X, Wang B, et al. Lactosylated gramicidin-based lipid nanoparticles (lac-gln) for targeted delivery of anti-mir-155 to hepatocellular carcinoma. J Control Release. 2013; 168: 251-261.
129. Babar IA, Cheng CJ, Booth CJ, et al. Nanoparticle-based therapy in an in vivo microrna-155 (mir-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A. 2012; 109: E1695-1704.
130. Xu Y, Xia F, Ma L, et al. Microrna-122 sensitizes hcc cancer cells to adriamycin and vincristine through modulating expression of mdr and inducing cell cycle arrest. Cancer Lett. 2011; 310: 160-169.
131. Fornari F, Milazzo M, Chieco P, et al. Mir-199a-3p regulates mtor and c-met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010; 70: 5184-5193.
132. Shimizu S, Takehara T, Hikita H, et al. The let-7 family of micrornas inhibits bcl-xl expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 2010; 52: 698-704.
133. Ling H, Fabbri M, Calin GA. Micrornas and other non-coding rnas as targets for anticancer drug development. Nat Rev Drug Discov. 2013; 12: 847-865.
134. Fan CG, Wang CM, Tian C, et al. Mir-122 inhibits viral replication and cell proliferation in hepatitis b virus-related hepatocellular carcinoma and targets ndrg3. Oncol Rep. 2011; 26: 1281-1286.
135. Coppola N, Potenza N, Pisaturo M, et al. Liver microrna hsa-mir-125a-5p in hbv chronic infection: Correlation with hbv replication and disease progression. PloS one. 2013; 8: e65336.
136. Park SO, Kumar M, Gupta S. Tgf-beta and iron differently alter hbv replication in human hepatocytes through tgf-beta/bmp signaling and cellular microrna expression. PloS one. 2012; 7: e39276.
137. Lee CG, Kim YW, Kim EH, et al. Farnesoid x receptor protects hepatocytes from injury by repressing mir-199a-3p, which increases levels of lkb1. Gastroenterology. 2012; 142: 1206-1217.
138. Henry JC, Park JK, Jiang J, et al. Mir-199a-3p targets cd44 and reduces proliferation of cd44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010; 403: 120-125.
139. Yang W, Sun T, Cao J, et al. Downregulation of mir-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res. 2012; 318: 944-954.
140. Shi C, Xu X. Microrna-22 is down-regulated in hepatitis b virus-related hepatocellular carcinoma. Biomed Pharmacother. 2013; 67: 375-380.
141. Wang CM, Wang Y, Fan CG, et al. Mir-29c targets tnfaip3, inhibits cell proliferation and induces apoptosis in hepatitis b virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2011; 411: 586-592.
142. Piskounova E, Polytarchou C, Thornton JE, et al. Lin28a and lin28b inhibit let-7 microrna biogenesis by distinct mechanisms. Cell. 2011; 147: 1066-1079.
143. Nam Y, Chen C, Gregory RI, et al. Molecular basis for interaction of let-7 micrornas with lin28. Cell. 2011; 147: 1080-1091.
144. Park SM, Shell S, Radjabi AR, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene hmga2. Cell Cycle. 2007; 6: 2585-2590.
145. Aguda BD, Kim Y, Piper-Hunter MG, et al. Microrna regulation of a cancer network: Consequences of the feedback loops involving mir-17-92, e2f, and myc. Proc Natl Acad Sci U S A. 2008; 105: 19678-19683.
146. Chen L, Zheng J, Zhang Y, et al. Tumor-specific expression of microrna-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther. 2011; 19: 1521-1528.
147. Yang X, Liang L, Zhang XF, et al. Microrna-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-stat3 pathway. Hepatology. 2013; 58: 158-170.
148. Wang L, Zhang X, Jia LT, et al. C-myc-mediated epigenetic silencing of microrna-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology. 2013.
149. Su H, Yang JR, Xu T, et al. Microrna-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009; 69: 1135-1142.
150. Li S, Fu H, Wang Y, et al. Microrna-101 regulates expression of the v-fos fbj murine osteosarcoma viral oncogene homolog (fos) oncogene in human hepatocellular carcinoma. Hepatology. 2009; 49: 1194-1202.
151. Lin CJ, Gong HY, Tseng HC, et al. Mir-122 targets an anti-apoptotic gene, bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008; 375: 315-320.
152. Yang XW, Zhang LJ, Huang XH, et al. Mir-145 suppresses cell invasion in hepatocellular carcinoma cells: Mir-145 targets adam17. Hepatol Res. 2013.
153. Wang Y, Lee AT, Ma JZ, et al. Profiling microrna expression in hepatocellular carcinoma reveals microrna-224 up-regulation and apoptosis inhibitor-5 as a microrna-224-specific target. J Biol Chem. 2008; 283: 13205-13215.